| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Bilirubin, Total
MessagePerformed in Chemistry
Test Code
BILIT
Alias/See Also
Bilirubin, Total
CPT Codes
82247
Preferred Specimen
Green Top LiHep, Plasma
Gold/Amber
WyMCC - SST
Note: Patients Less than 30 days old, Preferred Tube Type: Green/Gold/Amber Microtainer 1 mL
Patient Greater than 30 days old Preferred Tube Type: Green or Gold 4mL
Gold/Amber
WyMCC - SST
Note: Patients Less than 30 days old, Preferred Tube Type: Green/Gold/Amber Microtainer 1 mL
Patient Greater than 30 days old Preferred Tube Type: Green or Gold 4mL
Other Acceptable Specimens
Lavender Top EDTA, Gold/SST or Red Top
FDA Status
FDA Approved
Setup Schedule
Daily, Sunday through Saturday
Report Available
Less than 4 hours
Clinical Significance
Measurement of the levels of bilirubin, an organic compound formed during the
normal and abnormal destruction of red blood cells, is used in the diagnosis and
treatment of liver, hemolytic, hematological, and metabolic disorders, including
hepatitis and gall bladder blockage.
Bilirubin is formed in the reticuloendothelial system during the degradation of
aged erythrocytes. The heme portion from hemoglobin and form other hemecontaining proteins is removed, metabolized to bilirubin, and transported as a
complex with serum albumin to the liver. In the liver, bilirubin is conjugated with
glucuronic acid for solubilization and subsequent transport through the bile duct
and elimination via the digestive tract.
Diseases or conditions which, through hemolytic processes, produce bilirubin
faster than the liver can metabolize it, cause the levels of unconjugated (indirect)
bilirubin to increase in the circulation. Liver immaturity and several other diseases
in which the bilirubin conjugation mechanism is impaired cause similar elevations
of circulating unconjugated bilirubin. Bile duct obstruction or damage to
hepatocellular structure causes increases in the level of both conjugated (direct)
and unconjugated (indirect) bilirubin in the circulation.
normal and abnormal destruction of red blood cells, is used in the diagnosis and
treatment of liver, hemolytic, hematological, and metabolic disorders, including
hepatitis and gall bladder blockage.
Bilirubin is formed in the reticuloendothelial system during the degradation of
aged erythrocytes. The heme portion from hemoglobin and form other hemecontaining proteins is removed, metabolized to bilirubin, and transported as a
complex with serum albumin to the liver. In the liver, bilirubin is conjugated with
glucuronic acid for solubilization and subsequent transport through the bile duct
and elimination via the digestive tract.
Diseases or conditions which, through hemolytic processes, produce bilirubin
faster than the liver can metabolize it, cause the levels of unconjugated (indirect)
bilirubin to increase in the circulation. Liver immaturity and several other diseases
in which the bilirubin conjugation mechanism is impaired cause similar elevations
of circulating unconjugated bilirubin. Bile duct obstruction or damage to
hepatocellular structure causes increases in the level of both conjugated (direct)
and unconjugated (indirect) bilirubin in the circulation.
